SP 0230
Alternative Names: MenB - Sanofi Pasteur; Multicomponent meningococcal group B vaccine - Sanofi Pasteur; SP MenB vaccine; SP-0230Latest Information Update: 13 Aug 2024
Price :
$50 *
At a glance
- Originator Sanofi Pasteur
- Class Meningococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Meningococcal group B infections
Most Recent Events
- 10 Nov 2021 Phase-II clinical trials in Meningococcal group B infections (Combination therapy, In adolescents, In children, In infants, Prevention, In adults) in Puerto Rico, USA (IM) (Sanofi pipeline, November 2021)
- 10 Nov 2021 Phase-II clinical trials in Meningococcal group B infections (In adolescents, In children, In infants, Monotherapy, Prevention, In adults) in Puerto Rico, USA (IM) (Sanofi pipeline, November 2021)
- 29 Mar 2021 Phase-I/II clinical trials in Meningococcal group B infections (Combination therapy, Prevention, In infants, In children, In adolescents, In adults) in Puerto Rico, USA (IM) (NCT04825223)